Original researchAn integrated analysis of thirteen trials summarizing thelong-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy*
References (25)
- et al.
Cyclosporine consensus conference: With emphasis on the treatment of psoriasis
J Am Acad Dermatol
(1998) - et al.
A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis
J Am Acad Dermatol
(2002) Current concepts and review of alefacept in the treatment of psoriasis
Dermatol Clin
(2004)- et al.
The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: A cohort study
J Invest Dermatol
(2003) - et al.
CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: Results of a randomized study
J Am Acad Dermatol
(2003) - et al.
Treatment of psoriasis. Part 2. Systemic therapies
J Am Acad Dermatol
(2001) - et al.
Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study
J Natl Cancer Inst
(1998) The role of T cells in psoriasis
J Eur Acad Dermatol Venereol
(2003)- et al.
Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis
Eur J Dermatol
(2003) - et al.
Treatment of psoriasis with alefacept: Correlation of clinical improvement with reductions of memory T-cell counts
Arch Dermatol
(2003)
An international, randomized, double-blind, Placebocontrolled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis
Arch Dermatol
Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis
Dermatology
Cited by (65)
Psoriasis Therapy: Breakthroughs in Pharmacogenomics or in Pharmacology?
2016, Journal of Investigative DermatologyCorrelation among Hypoglycemia, Glycemic Variability, and C-Peptide Preservation after Alefacept Therapy in Patients with Type 1 Diabetes Mellitus: Analysis of Data from the Immune Tolerance Network T1DAL Trial
2016, Clinical TherapeuticsCitation Excerpt :Maintenance of islet preservation for extended periods may require additional courses of treatment. In psoriasis, up to 9 courses of alefacept therapy have been given during a 5-year period with no evidence of increased toxic effects with repeated exposure.47 Moreover, recent studies suggest it may be possible to lengthen the interval between doses of biologics in psoriasis,48 which could also be considered during the further development of alefacept for the treatment of T1D.
Immune Compromise Associated with Biologics
2014, Stiehm's Immune DeficienciesBiologic systemic therapy for moderate-to-severe psoriasis: A review
2013, Journal of Taibah University Medical SciencesCitation Excerpt :Given infliximab’s characteristic rapid onset of action and high response rates, it is recommended when rapid disease control is required in unstable conditions such as erythrodermic or pustular psoriasis.44 The recommended dosing regimen for infliximab is a 5 mg/kg IV infusion, to be repeated at 2, 6, and then every 8 weeks thereafter.65 Clinical effect can be expected in 1–2 weeks.57
Iatrogenic effects of biologics for psoriasis
2011, Clinics in DermatologyThe safety profile and sustained remission associated with response to multiple courses of intramuscular alefacept for treatment of chronic plaque psoriasis
2010, Journal of the American Academy of Dermatology
- *
This work was presented in part at the International Psoriasis Symposium, June 9–13, 2004, Montreal, Quebec, Canada; the Academy of Managed Care Pharmacy Fall Educational Conference, October 13–16, 2004, Baltimore, Maryland; the 63rd Annual Meeting of the American Academy of Dermatology, February 18–22, 2005, New Orleans, Louisiana; the Australasian College of Dermatologists Meeting, May 15–18, 2005, Perth, Australia; and the 80th Annual Conference of the Canadian Dermatology Association, June 28 July 3, 2005, Quebec City, Quebec, Canada.